The Kaplan-Meier survival analysis showed differences for lung cancer-specific survival between non-diabetic and diabetic patients by antihyperglycemic medication user groups, with better survival in the groups of insulin and metformin users (Figure 2 and Figure 3). The gene discussed is INS; the disease is lung carcinoma.